Literature DB >> 15389537

Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.

Roberta Di Pietro1, Giorgio Zauli.   

Abstract

Tumor necrosis factor (TNF) is a cytokine that mediates tumor necrosis. To date, 20 different members of the TNF super-family and 21 different receptors have been identified. All ligands of the TNF super-family have been found to activate transcription factor NF-kappa B and c-Jun kinase. Members of this family have diverse biological effects, including induction of apoptosis, promotion of cell survival, and regulation of the immune system and hematopoiesis. The current review focuses on the biological effects of TNF-related apoptosis-inducing ligand (TRAIL), a TNF super-family member which, a few years ago, generated considerable enthusiasm for its anticancer activity, not accompanied by general toxicity in most normal tissues and organs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15389537     DOI: 10.1002/jcp.20099

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  38 in total

1.  In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody.

Authors:  Giorgio Zauli; Federica Corallini; Sonia Zorzet; Vittorio Grill; Roberto Marzari; Paola Secchiero
Journal:  Invest New Drugs       Date:  2010-08-17       Impact factor: 3.850

2.  The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL.

Authors:  Francesco Carinci; Lorenzo Monasta; Corrado Rubini; Daniela Stramazzotti; Annalisa Palmieri; Elisabetta Melloni; Alex Knowles; Luca Ronfani; Giorgio Zauli; Paola Secchiero
Journal:  Invest New Drugs       Date:  2010-11-18       Impact factor: 3.850

3.  TRAIL shows potential cardioprotective activity.

Authors:  Barbara Toffoli; Stella Bernardi; Riccardo Candido; Serena Zacchigna; Bruno Fabris; Paola Secchiero
Journal:  Invest New Drugs       Date:  2011-01-04       Impact factor: 3.850

4.  TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.

Authors:  Johannes Lemke; Andreas Noack; Dieter Adam; Vladimir Tchikov; Uwe Bertsch; Christian Röder; Stefan Schütze; Harald Wajant; Holger Kalthoff; Anna Trauzold
Journal:  J Mol Med (Berl)       Date:  2010-03-31       Impact factor: 4.599

5.  Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.

Authors:  Esther P Jane; Daniel R Premkumar; Ian F Pollack
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

6.  β-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt.

Authors:  Laurel A Grisanti; Jennifer A Talarico; Rhonda L Carter; Justine E Yu; Ashley A Repas; Scott W Radcliffe; Hoang-Ai Tang; Catherine A Makarewich; Steven R Houser; Douglas G Tilley
Journal:  J Mol Cell Cardiol       Date:  2014-02-22       Impact factor: 5.000

Review 7.  NF-κB pathways in hematological malignancies.

Authors:  Chiara Gasparini; Claudio Celeghini; Lorenzo Monasta; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2014-01-14       Impact factor: 9.261

Review 8.  TNF superfamily: a growing saga of kidney injury modulators.

Authors:  Maria D Sanchez-Niño; Alberto Benito-Martin; Sara Gonçalves; Ana B Sanz; Alvaro C Ucero; Maria C Izquierdo; Adrian M Ramos; Sergio Berzal; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Mediators Inflamm       Date:  2010-10-04       Impact factor: 4.711

9.  Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.

Authors:  Piya Chaemsaithong; Roberto Romero; Steven J Korzeniewski; Alyse G Schwartz; Tamara Stampalija; Zhong Dong; Lami Yeo; Edgar Hernandez-Andrade; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2013-04-22

10.  Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.

Authors:  D Mahalingam; A Natoni; M Keane; A Samali; E Szegezdi
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.